Echosens

Echosens is a pioneer and global leader in non-invasive liver diagnostics, with its FibroScan® technology established as the clinical gold standard for assessing liver fibrosis and steatosis. The company has a vast installed base of over 6,500 devices in more than 127 countries, supported by extensive clinical validation including over 6,270 peer-reviewed publications and inclusion in 250+ international guidelines. Echosens is expanding its platform from a diagnostic device into a broader liver health management ecosystem through cloud-based data solutions, integrated biomarker scores, and targeted initiatives in pharmaceutical partnerships and direct-to-patient awareness.

Vibration-Controlled Transient Elastography (VCTE™) and Controlled Attenuation Parameter (CAP™) for non-invasive measurement of liver stiffness (fibrosis) and liver steatosis (fat).

Echosens' FibroScan® is the established gold standard in liver elastography. Key competitors include other point-of-care elastography devices (e.g., Siemens Healthineers' Acuson systems with shear wave), MRI-based elastography (offered by GE, Siemens), and numerous serum biomarker panels. FibroScan's main advantages are its dedicated design, extensive clinical validation, standardization, and widespread guideline inclusion.